Literature DB >> 27286276

Markers of tolerance development to food allergens.

M Ponce1, S C Diesner1, Z Szépfalusi1, T Eiwegger2,3.   

Abstract

IgE-mediated reactions to food allergens are the most common cause of anaphylaxis in childhood. Although allergies to cow's milk, egg, or soy proteins, in contrast to peanut and tree nut allergens, resolve within the first 6 years of life in up to 60% due to natural tolerance development, this process is not well understood. At present, there is no cure or treatment for food allergy that would result in an induction of tolerance to the symptom-eliciting food. Avoidance, providing an emergency plan and education, is the standard of treatment. Oral immunotherapeutic approaches have been proven reasonable efficacy; however, they are associated with high rates of side-effects and low numbers of patients achieving tolerance. Nevertheless, mechanisms that take place during oral immunotherapy may help to understand tolerance development. On the basis of these therapeutic interventions, events like loss of basophil activation and induction of regulatory lymphocyte subsets and of blocking antibodies have been described. Their functional importance at a clinical level, however, remains to be investigated in detail. Consequently, there is eminent need to understand the process of tolerance development to food allergens and define biomarkers to develop and monitor new treatment strategies for food allergy.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  food allergens; food allergy; marker; oral immunotherapy; tolerance

Mesh:

Substances:

Year:  2016        PMID: 27286276     DOI: 10.1111/all.12953

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  5 in total

1.  Dietary Intervention with β-Lactoglobulin-Derived Peptides and a Specific Mixture of Fructo-Oligosaccharides and Bifidobacterium breve M-16V Facilitates the Prevention of Whey-Induced Allergy in Mice by Supporting a Tolerance-Prone Immune Environment.

Authors:  Atanaska I Kostadinova; Alba Pablos-Tanarro; Mara A P Diks; Betty C A M van Esch; Johan Garssen; Léon M J Knippels; Linette E M Willemsen
Journal:  Front Immunol       Date:  2017-10-23       Impact factor: 7.561

2.  Therapeutic vaccines for allergic disease.

Authors:  Danuta Gutowska-Owsiak; Graham S Ogg
Journal:  NPJ Vaccines       Date:  2017-05-08       Impact factor: 7.344

Review 3.  Alternatives to Cow's Milk-Based Infant Formulas in the Prevention and Management of Cow's Milk Allergy.

Authors:  Natalia Zofia Maryniak; Ana Isabel Sancho; Egon Bech Hansen; Katrine Lindholm Bøgh
Journal:  Foods       Date:  2022-03-23

4.  Retinoic acid prevents immunogenicity of milk lipocalin Bos d 5 through binding to its immunodominant T-cell epitope.

Authors:  Karin Hufnagl; Debajyoti Ghosh; Stefanie Wagner; Alessandro Fiocchi; Lamia Dahdah; Rodolfo Bianchini; Nina Braun; Ralf Steinborn; Martin Hofer; Marion Blaschitz; Georg A Roth; Gerlinde Hofstetter; Franziska Roth-Walter; Luis F Pacios; Erika Jensen-Jarolim
Journal:  Sci Rep       Date:  2018-01-25       Impact factor: 4.379

Review 5.  Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma.

Authors:  Heimo Breiteneder; Ya-Qi Peng; Ioana Agache; Zuzana Diamant; Thomas Eiwegger; Wytske J Fokkens; Claudia Traidl-Hoffmann; Kari Nadeau; Robyn E O'Hehir; Liam O'Mahony; Oliver Pfaar; Maria J Torres; De-Yun Wang; Luo Zhang; Cezmi A Akdis
Journal:  Allergy       Date:  2020-09-30       Impact factor: 14.710

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.